Purpose: To develop a contrast-enhanced ultrasound algorithm (LI-RADS-CEUS = Liver Imaging
Reporting and Data System with contrast-enhanced ultrasound) for the diagnosis of
hepatocellular carcinoma (HCC) in patients at risk.
Materials and methods: A contrast-enhanced ultrasound algorithm (LI-RADS-CEUS) was designed analogous to
CT-and MRI-based LI-RADS. LI-RADS-CEUS was evaluated retrospectively in 50 patients
at risk with confirmed diagnosis of HCC or Non-HCC lesions (test group) with subsequent
validation in a prospective cohort of 50 patients at risk for HCC (validation group).
Results were compared to histology, CE-CT and CE-MRI as reference standards.
Results: Tumour diagnosis in the retrospective versus prospective patient cohort (n = 50/50)
were 46/41 HCCs, 3/3 intrahepatic cholangiocellular carcinomas (ICCs) and 1/6 benign
lesions. Diagnostic accuracy of LI-RADS-CEUS for HCC, ICC and Non-HCC-non-ICC-lesions
was 89%. For the diagnosis of HCC, diagnostic accuracy was 93.5% (43/46 cases) in
the test group and 95.1% (39/41 cases) in the validation group. Sensitivity, specificity,
positive (PPV) and negative predictive value (NPV) were 94.3%/66.6%/94.3% and 66.6%,
respectively (mean values from both cohorts). Histological findings of HCC were available
in 40 versus 23 cases (in total: G1/G2/G3: 15/35/13). Arterial hyperenhancement was
seen in 68/87 (78.2%) of HCCs. Arterial hyperenhancement with subsequent portal venous
or late phase hypoenhancement was seen in 66% of HCCs.
Conclusion: LI-RADS-CEUS offers a CEUS algorithm for standardised assessment and reporting of
focal liver lesions in patients at risk for HCC. Arterial hyperenhancement in CEUS
is the key feature for the diagnosis of HCC in patients at risk, whereas washout is
not a necessary prerequisite.
